Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 COVID-19 vaccine in lung cancer patients receiving chemotherapy
jRCT1071210024Completed
- Sponsor
- Kameda Medical Center
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kameda Medical Center. Primary endpoint: Immunogenicity. Started May 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1071210024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071210024.